Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 3 | 1 |
List of Figures | 4 | 1 |
Report Guidance | 5 | 1 |
Clinical Trials by Region | 6 | 9 |
Clinical Trials and Average Enrollment by Country | 7 | 3 |
Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 10 | 1 |
Top Five Countries Contributing to Clinical Trials in Europe | 11 | 1 |
Top Countries Contributing to Clinical Trials in North America | 12 | 1 |
Top Countries Contributing to Clinical Trials in Middle East and Africa | 13 | 1 |
Top Countries Contributing to Clinical Trials in Central and South America | 14 | 1 |
Clinical Trials by G7 Countries: Proportion of Focal Segmental Glomerulosclerosis (FSGS) to Genito Urinary System And Sex Hormones Clinical Trials | 15 | 2 |
Clinical Trials by Phase in G7 Countries | 17 | 1 |
Clinical Trials in G7 Countries by Trial Status | 18 | 1 |
Clinical Trials by E7 Countries: Proportion of Focal Segmental Glomerulosclerosis (FSGS) to Genito Urinary System And Sex Hormones Clinical Trials | 19 | 2 |
Clinical Trials by Phase in E7 Countries | 21 | 1 |
Clinical Trials in E7 Countries by Trial Status | 22 | 1 |
Clinical Trials by Phase | 23 | 2 |
In Progress Trials by Phase | 24 | 1 |
Clinical Trials by Trial Status | 25 | 1 |
Clinical Trials by End Point Status | 26 | 1 |
Subjects Recruited Over a Period of Time | 27 | 1 |
Clinical Trials by Sponsor Type | 28 | 1 |
Prominent Sponsors | 29 | 3 |
Top Companies Participating in Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials | 30 | 2 |
Prominent Drugs | 32 | 1 |
Latest Clinical Trials News on Focal Segmental Glomerulosclerosis (FSGS) | 33 | 1 |
Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis | 33 | 1 |
Clinical Trial Profile Snapshots | 34 | 35 |
Appendix | 69 | 3 |
Abbreviations | 69 | 1 |
Definitions | 69 | 1 |
Research Methodology | 70 | 1 |
Secondary Research | 70 | 1 |
About GlobalData | 71 | 1 |
Contact Us | 71 | 1 |
Disclaimer | 71 | 1 |
Source | 72 | 1 |